25.02.2019 • NewsDede Willamsineos styrolutionTotal

Styrolution Completes China Deal with Total

Styrolution Completes China Deal with Total (c) Ineos
Styrolution Completes China Deal with Total (c) Ineos

Germany-based Ineos Styrolution has completed its acquisition of Total’s Chinese wholly owned polystyrene business, including two production sites in Ningbo and Foshan and two related offices in Guangzhou and Shanghai belonging to the French energy and petrochemicals group Total.

The deal was announced in August 2018.

Total’s Ningbo plant, which employs 54 people, produces 200,000 t/y of PS. A facility for polypropylene compounds at the site, supplying the automotive sector, will produce exclusively for Total in future.

The Foshan plant has capacity for 200,000 t/y of PS and employs 86 people.

Steve Harrington, president of Ineos’ Asia Pacific and global styrene monomer division, called the acquisition “an important milestone for both Ineos Styrolution and the Ineos group,” as it represents its first manufacturing asset in China and provides access to the Chinese market with locally produced material.

In addition, Harrington said, “the two new plants provide us with a platform to further develop our manufacturing base in China.”

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.